Fragile X Syndrome

Rare Diseases
5
Pipeline Programs
4
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
5
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
2 programs
2
CBD Oral SolutionPhase 21 trial
CBD Oral SolutionPhase 21 trial
Active Trials
NCT06261502Not Yet Recruiting40Est. Dec 2027
NCT06261450Not Yet Recruiting50Est. Dec 2027
Healx
HealxUK - Cambridge
2 programs
2
GaboxadolPhase 21 trial
SulindacPhase 21 trial
Active Trials
NCT06334419CompletedEst. Jun 2025
NCT04823052WithdrawnEst. Oct 2022
Mirum Pharmaceuticals
Mirum PharmaceuticalsFOSTER CITY, CA
1 program
1
Low dose of MRM-3379Phase 21 trial
Active Trials
NCT07209462Recruiting60Est. Oct 2027
M&
Merck & Co.RAHWAY, NJ
1 program
Behavior analytic treatmentN/A1 trial
Active Trials
NCT03510156CompletedEst. Mar 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Mirum PharmaceuticalsLow dose of MRM-3379
Jazz PharmaceuticalsCBD Oral Solution
Jazz PharmaceuticalsCBD Oral Solution
HealxGaboxadol
HealxSulindac
Merck & Co.Behavior analytic treatment

Clinical Trials (6)

Total enrollment: 150 patients across 6 trials

Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)

Start: Nov 2025Est. completion: Oct 202760 patients
Phase 2Recruiting

Effect of CANnabidiol on Anxiety and GABAergic Function in Individuals with Fragile-X Syndrome

Start: May 2025Est. completion: Dec 202740 patients
Phase 2Not Yet Recruiting

Effect of CBD on the Brain

Start: May 2025Est. completion: Dec 202750 patients
Phase 2Not Yet Recruiting

Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS)

Start: Jan 2024Est. completion: Jun 2025
Phase 2Completed

Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40

Start: May 2022Est. completion: Oct 2022
Phase 2Withdrawn
NCT03510156Merck & Co.Behavior analytic treatment

Treatment of Disruptive Behaviors in Fragile X Syndrome

Start: Jul 2016Est. completion: Mar 2022
N/ACompleted

Related Jobs in Rare Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 150 patients
4 companies competing in this space